Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05417945
Other study ID # LT-2021-06
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 2022
Est. completion date December 2024

Study information

Verified date June 2022
Source Jenscare Scientific
Contact Shengshou Hu
Phone 18616900716
Email guyongxin@jenscare.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The clinical trial study is designed as a prospective, multicenter, single-group target value clinical study to evaluate the safety and efficacy of the clinical investigational product and to evaluate its performance using the above clinical trial primary endpoint and secondary endpoint indicators.


Description:

Transcatheter mitral valve repair system is derived from the "Edge-to-Edge" technique in traditional surgery. The principle is roughly to clamp the midpoint of the anterior leaflet and the midpoint of the posterior leaflet of the mitral valve to form a double-hole inflow channel and then improve the regurgitation.Using the JensClip transcatheter valve repair system for the treatment of patients with moderate-severe or severe degenerative mitral regurgitation who are at high surgical risk.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 124
Est. completion date December 2024
Est. primary completion date May 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years; - Echocardiographically confirmed moderate-severe or severe degenerative mitral regurgitation (regurgitation degree MR = 3+); - NYHA Classification II-IV. - LVEF = 20% - Patients considered at high surgical risk after evaluation by two or more cardiovascular specialists (American Association for Thoracic Surgery STS score: risk of death from mitral valve repair = 6% or from mitral valve replacement = 8% (high risk); or the presence of 2 or more indices of frailty (moderate to severe frailty); or the presence of 2 or more major organ insufficiencies that do not improve postoperatively; or a comprehensive cardiac team assessment that the patient has other combined diseases or factors that make him or her unsuitable for surgery) - Anatomically suitable for mitral valve repair and assessed as suitable for use of this investigational device. - Voluntarily participate and sign an informed consent form and be willing to accept relevant examinations and clinical follow-up. Exclusion Criteria: - Severe mitral valve calcification - Previous implantation of a prosthetic mitral valvuloplasty ring or prosthetic mitral valve, or previous transcatheter mitral valve surgery - Patients with active infective endocarditis - Patients with mitral stenosis - Any intracardiac mass, left ventricular or atrial thrombus detected by echocardiography - Severe coronary stenosis without surgical or interventional treatment or an acute myocardial infarction within 90 days - Combined with tricuspid, aortic valve or severe macrovascular pathology requiring surgical or interventional treatment - Severe pulmonary hypertension (pulmonary artery systolic pressure > 70 mmHg measured by ultrasound or right heart catheter, if measured at the same time the right heart catheter measurement shall prevail). - Patients with severe right heart insufficiency - Hemodynamic instability, defined as systolic blood pressure <90 mmHg in the absence of afterload-reducing drugs, cardiogenic shock, or use of intra-aortic balloon pump; - Had a stroke/transient ischemic attack (TIA) within 30 days or severe carotid stenosis (> 70% stenosis on ultrasonography) - Have undergone transcatheter cardiovascular intervention (PCI) within 30 days, or cardiovascular surgery within 180 days - Have had a pacemaker or cardioverter-defibrillator (ICD) implanted, or have undergone cardiac resynchronization therapy (CRT, CRT-D) within 30 days - Patients with clear coagulation disorders and severe coagulation disorders, or with clear contraindications to the anticoagulant drugs - Known hypersensitivity to product composition - Patients with severe neurological pathology affecting cognitive ability - Patients with a life expectancy of < 12 months - Have undergone a heart transplant or have recently been allocated a heart transplant donor - Being enrolled in an interventional clinical study of another device or drug - Patients diagnosed with hypertrophic cardiomyopathy, restrictive cardiomyopathy, infiltrative cardiomyopathy (e.g., amyloidosis, hemochromatosis), dilated cardiomyopathy, or constrictive pericarditis - Patients who are pregnant or planning to become pregnant within the next 12 months. Note: Female patients of childbearing age are required to undergo a pregnancy test within 14 days prior to the operation and the result should be negative, and additionally they should use a confirmed method of contraception - Other conditions that the investigator considers inappropriate for participation in this clinical study

Study Design


Related Conditions & MeSH terms


Intervention

Device:
JensClip transcatheter valve repair system
Transcatheter mitral valve repair system is derived from the "Edge-to-Edge" technique in traditional surgery. The principle is roughly to clamp the midpoint of the anterior leaflet and the midpoint of the posterior leaflet of the mitral valve to form a double-hole inflow channel and then improve the regurgitation.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Jenscare Scientific

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical success rate at 12 months postoperatively Clinical success is defined as no death, no mitral valve-related surgical procedures due to mitral valve incompetence, and no moderate-severe or severe mitral regurgitation (MR > 2+), with the primary evaluation indicators determined by the Core Laboratory and Clinical Event Committee (CEC). 12 months
See also
  Status Clinical Trial Phase
Completed NCT02520310 - AVJ-514 Japan Trial N/A
Not yet recruiting NCT06465745 - AltaValve Pivotal Trial N/A
Completed NCT02355418 - The Role of Myocardial Fibrosis in Degenerative Mitral Regurgitation
Recruiting NCT04577248 - The Prospecive OBSERVational Munich Interventional MITRAl-Valve Registry
Recruiting NCT03242642 - Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. N/A
Recruiting NCT02961647 - Hemodynamic Stress Test in Severe Mitral Regurgitation (HEMI) N/A
Active, not recruiting NCT02302872 - Treatment of Heart Failure and Associated Functional Mitral Valve Regurgitation N/A
Completed NCT01777815 - Safety and Performance Study of the NeoChord Device N/A
Withdrawn NCT00428103 - Effects of Mitral Valve Repair With the Geoform Ring on Cardiomyopathy N/A
Completed NCT04351984 - Transcatheter Mitral Valvuloplasty Pilot Study
Withdrawn NCT02722551 - CardiAQ-Edwards™ Transcatheter Mitral Valve Replacement (TMVR) Study Phase 1/Phase 2
Active, not recruiting NCT02321514 - Expanded Clinical Study of the Tendyne Mitral Valve System N/A
Recruiting NCT02245763 - STS/ACC TVT Registry Mitral Module
Active, not recruiting NCT01740583 - Mitralign Percutaneous Annuloplasty System for Chronic Functional Mitral Valve Regurgitation N/A
Completed NCT00800046 - A Study of Percutaneous Repair of Functional Mitral Regurgitation Using the Ancora Heart, Inc. AccuCinch® Ventricular Repair System - The CINCH-2 Study N/A
Completed NCT00415701 - Effect of Etomidate on Hemodynamics and Adrenocortical Function After Cardiac Surgery Phase 4
Recruiting NCT03908983 - OPtimisation of Surgical Repair for Treating Insufficiency of the MItral Valve - Safety and Effectiveness Evaluation N/A
Active, not recruiting NCT04818502 - Real World Study of the Tendyne™ Mitral Valve System to Treat Mitral Regurgitation
Terminated NCT03285724 - Safety and Performance Study of the Harpoon Mitral Valve Repair System N/A
Recruiting NCT04195984 - Mi-thos® Transcatheter Mitral Valve Replacement Study N/A